Eton Pharmaceuticals (ETON) Accumulated Expenses (2017 - 2026)

Eton Pharmaceuticals has disclosed Accumulated Expenses across 10 years of filings, most recently posting $10.9 million for Q2 2026.

• In Q2 2026, Accumulated Expenses rose 46.47% year-over-year to $10.9 million; the TTM figure through Jun 2026 stood at $10.9 million (up 46.47% YoY), while the FY2025 annual figure was $9.4 million, up 5.54% from the prior year.
• Accumulated Expenses came in at $10.9 million for Q2 2026 at Eton Pharmaceuticals, up from $9.4 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $11.4 million in Q2 2024 to a low of $48000.0 in Q3 2024.
• Average Accumulated Expenses over 5 years is $6.2 million, with a median of $7.1 million recorded in 2023.
• Year-over-year, Accumulated Expenses sank 99.33% in 2024 and jumped 18893.75% in 2025.
• Over 5 years, Accumulated Expenses stood at $3.7 million in 2022, then soared by 47.08% to $5.4 million in 2023, then surged by 65.5% to $8.9 million in 2024, then gained by 5.54% to $9.4 million in 2025, then advanced by 16.12% to $10.9 million in 2026.
• Per Business Quant data, the three most recent Accumulated Expenses figures were $10.9 million in Q2 2026, $9.4 million in Q4 2025, and $9.1 million in Q3 2025.